🇪🇺 Fareston in European Union

EMA authorised Fareston on 14 February 1996

Marketing authorisation

EMA — authorised 14 February 1996

  • Application: EMEA/H/C/000091
  • Marketing authorisation holder: Orion Corporation
  • Local brand name: Fareston
  • Indication: First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.
  • Status: approved

Read official source →

Fareston in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Fareston approved in European Union?

Yes. EMA authorised it on 14 February 1996.

Who is the marketing authorisation holder for Fareston in European Union?

Orion Corporation holds the EU marketing authorisation.